Information Provided By: 
Fly News Breaks for December 7, 2015
BLUE
Dec 7, 2015 | 07:07 EDT
JPMorgan analyst Cory Kasimov points out that the relatively low/slow response observed in bluebird bio's data over the weekend occurred in only two sickle cell disease patients. The data on the two patients was disappointing relative to the first subject, who remains effectively "cured," Kasimov tells investors in a research note. Watching a product evolve patient-by-patient seems to be the new norm in biotech, which is unfortunate, Kasimov contends. He maintains an Overweight rating on bluebird with a $164 price target.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
